Prime-boost interval matters: A randomized phase 1 study to identify the minimum interval necessary to observe the h5 dna influenza vaccine priming effect

Journal of Infectious Diseases

Volumn 208, Issue 3, 2013, Pages 418-422

  Ledgerwood, Julie E ^a   Zephir, Kathryn ^a   Hu, Zonghui ^a   Wei, Chih Jen ^a   Chang, Leejah ^a   Enama, Mary E ^a   Hendel, Cynthia S ^a   Sitar, Sandra ^a   Bailer, Robert T ^a   Koup, Richard A ^a   Mascola, John R ^a   Nabel, Gary J ^a   Graham, Barney S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Avian influenza; boost interval; DNA vaccine; H5N1; hemagglutination inhibition

Indexed keywords

H5 DNA VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; MONOVALENT INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; CROSS REACTION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEOMETRIC MEAN TITER; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; INFECTION PREVENTION; INFLUENZA A (H5N1); MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION;

AVIAN INFLUENZA; BOOST INTERVAL; DNA VACCINE; H5N1; HEMAGGLUTINATION INHIBITION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA VACCINES; MALE; MIDDLE AGED; TIME FACTORS; VACCINES, DNA; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84880191764     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit180     Document Type: Article

References (15)

1. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343-51.
2. WHO. Confirmed human cases of avian influenza A(H5N1). http://www.who.int/csr/disease/avian-influenza/country/cases-table-2011-06- 16/en/index.html. Accessed 14 August 2011.
3. Enserink M, Malakoff D. Biosecurity. Will flu papers lead to new research oversight? Science 2012; 335:20.-22.
4. Kawaoka Y. H5N1: Flu transmission work is urgent. Nature 2012; 482:155.
5. Ledgerwood JE, Wei CJ, Hu Z, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011; 11:916-24.
6. Wei CJ, Boyington JC, McTamney PM, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010; 329:1060-4.
7. Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006; 13:1267-77.
8. Wei C-J, Boyington JC, Dai K, et al. Cross-Neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med 2010; 2:24ra1.
9. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythro-cytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004; 103:91-5.
10. Wei CJ, Xu L, Kong WP, et al. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol 2008; 82:6200-8.
11. Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immu-nogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006; 194:1638-49.
12. Catanzaro AT, Roederer M, Koup RA, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007; 25:4085-92.
13. Ledgerwood JE, Graham BS. DNA vaccines: a safe and efficient platform technology for responding to emerging infectious diseases. Hum Vaccin 2009; 5:623-6.
14. Ledgerwood JE, Pierson TC, Hubka SA, et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 2011; 203:1396-404.
15. Wu L, Kong WP, Nabel GJ. Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J Virol 2005; 79: 8024-31.